Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Maria Francesca AllegaCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0003-0952-8496
Ruhi DeshmukhCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-9700-8556
Theresa HillingerMedical University of Vienna, Comprehensive Cancer Center, Center for Cancer Research, Vienna 1090, Austria.
Alena AkhmetshinaMedical University of Vienna, Comprehensive Cancer Center, Center for Cancer Research, Vienna 1090, Austria.ORCID 0000-0002-2346-7258
Anaïs OudinNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, L-1210 Luxembourg, Luxembourg.ORCID 0000-0001-5552-9823
Robert BielikCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.
Dmitry SolovievCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-1324-3197
Victor H VillarCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0003-2837-5018
Tobias AckermannCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-9982-8697
Sandeep K ChahalSchool of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.ORCID 0000-0001-5419-040X
Katrina H StevensonSchool of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.ORCID 0000-0002-7612-1453
Colin NixonCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-8085-2160
Robin ShawCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0001-5503-5233
Gillian M MorrisonCancer Research UK Scotland Centre and Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, EH16 4UU, UK.
Anthony J ChalmersSchool of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.ORCID 0000-0002-1746-7278
Steven M PollardCancer Research UK Scotland Centre and Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, EH16 4UU, UK.ORCID 0000-0001-6428-0492
Morten Lund-JohansenDepartment of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
Rolf BjerkvigDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Simone P NiclouNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, L-1210 Luxembourg, Luxembourg.ORCID 0000-0002-3417-9534
Einar O Vik-MoVilhelm Magnus Laboratory, Institute for Surgical Research and Department of Neurosurgery and Oslo University Hospital, Oslo, Norway.
David Y LewisCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0001-9329-1326
David SumptonCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-9004-4079
Saverio TarditoCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-5294-8683
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Steroid anti-inflammatory drugs, such as dexamethasone, are routinely used to manage brain tumor-associated edema, yet their impact on brain tumor metabolism remains understudied. Here, a metabolomic screen in naïve glioblastoma cells treated with dexamethasone revealed the accumulation of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma. · full record | Socratic